US Intravenous Immunoglobulin Market Forecast to 2028 - Country Analysis By Type, Application, Distribution Channel, and End User

Description

List of Tables

The US intravenous immunoglobulin market size was valued at US$ 4,439.26 million in 2022 and is projected to reach US$ 7,105.63 million by 2028; it is estimated to grow at a CAGR 8.2% during 2023-2028. The increasing geriatric population favors the growth of the US intravenous immunoglobulin market.

Immunoglobulins are the antibodies produced naturally by the body's immune system, which help fight infection and disease. Individuals with immunoglobulin deficiency require the external administration of immunoglobulin and known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIgs are extracted from human plasma. These antibodies are used in the treatment of various immunological, hematological, and neurological illnesses. Factors such as rising immunodeficiency disease prevalence and increasing geriatric population in the US drive the US intravenous immunoglobulin market growth. However, adverse effects of immunoglobulin therapy hamper the market growth.

IVIGs are used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. The IVIG is a standard therapy to treat most primary immunodeficiencies (PIDs). According to data by John Hopkins Medicine, ~3% of the total US population, i.e., 10 million people, suffers from autoimmune diseases. As per the National Institute of Allergy and Infectious Diseases (NIAID), there are over 200 different types of primary immune deficiency diseases (PIDDs) affecting ~500,000 people in the US. The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. The Rare Diseases Organization states that the incidence rate of ITP in adults is ~3.3 per 100,000 per year in the US. Per the National Multiple Sclerosis Society study report, published in 2019, ~1 million adults (~913,925) were affected by multiple sclerosis (MS) in the US. According to the MS Discovery Forum, ~200 new cases are diagnosed each week in the US. Thus, the increasing prevalence of immunodeficiency diseases drives the growth of the US intravenous immunoglobulin market.

Many market players and research institutes operating in the US intravenous immunoglobulin market are developing advanced technologies to expand their product portfolios and increase their market shares. Rising immunodeficiency disease prevalence, product approvals, and collaborations are among the factors driving the US intravenous immunoglobulin market size.

A few of the recent developments related to US intravenous immunoglobulin are mentioned below:

In April 2020, Kamada Ltd. and Kedrion Biopharma collaborated to develop, manufacture, and distribute a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment against COVID-19. The announcement follows separate previous reports by the two entities concerning initiating development programs for such products.

In January 2022, LFB and Kedrion joined forces in an industrial cooperation agreement to increase the availability of immunoglobulins for patients in France. In the framework of this industrial partnership, Kedrion manufactured immunoglobulins in Hungary from LFB plasma which was collected in France by the "Etablissement Francais du Sang" (EFS). LFB imported these immunoglobulins manufactured by Kedrion in France and complemented its immunoglobulins, which are available in hospitals across France, in agreement with and under the control of French health authorities.

In April 2020, In April 2020, Octapharma collaborated with CSL, Takeda, BPL, Biotest, and LFB to investigate the possibility of treating COVID-19 with plasma-derived hyperimmune immunoglobulins.

US Intravenous Immunoglobulin Market, By Type-Based Insights

Based on product type, the US intravenous immunoglobulin market is segmented into IgG, IgM, IgA, and others. In 2022, the IgG segment held the largest share of the market. Moreover, the same segment is expected to record the highest CAGR during the forecast period.

IVIg is a replacement therapy and treatment for patients with antibody deficiencies or for those who suffer from immunodeficiency disorders. For instance, in primary or secondary hypogammaglobulinemia, IVIg replacement therapy provides protection against infections by administering an adequate volume of IgG in the blood. IVIg is a blood product prepared from serum derived from 1,000-15,000 donors per batch where only IgG is purified from plasma to produce IVIg products. Therefore, IVIg used for treatment therapies contains 95-98% pure IgG with small amounts of other plasma proteins, including IgA and IgM.

Thus, wide applications of IgG in treating several categories of disorders are among the factors contributing to the growth of the US intravenous immunoglobulin market.

US Intravenous Immunoglobulin Market, By End User-Based Insights

The US intravenous immunoglobulin market, based on end user, is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. In 2022, the immunodeficiency diseases segment held the largest market share in . The same segment is expected to grow at the fastest rate during the coming years.

The World Health Organization (WHO), the US Census Bureau, and the US National Library of Medicine are a few of the major primary and secondary sources referred to while preparing the report on the US intravenous immunoglobulin market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US intravenous immunoglobulin market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the US intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Germany market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Product Code: TIPRE00029893

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Intravenous Immunoglobulin Market - By Type
- 1.3.2 Intravenous Immunoglobulin Market - By Application
- 1.3.3 Intravenous Immunoglobulin Market - By Distribution Channel
- 1.3.4 Intravenous Immunoglobulin Market - By End User
- 1.3.5 Intravenous Immunoglobulin Market - By Country

2. Intravenous Immunoglobulin Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Intravenous Immunoglobulin Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 US - PEST Analysis
4.3 Expert Opinion
4.4 Pipeline Product

5. United States Intravenous Immunoglobulin Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Immunodeficiency Disease Prevalence
- 5.1.2 Increasing Geriatric Population
5.2 Market Restraints
- 5.2.1 Adverse Effects of Immunoglobulin Therapy
5.3 Market Opportunities
- 5.3.1 Flourishing Pharmaceutical Industry
5.4 Future Trends
- 5.4.1 Strong Pipeline of IVIG Candidates
5.5 Impact Analysis

6. Intravenous Immunoglobulin Market - US Analysis

6.1 United States Intravenous Immunoglobulin Market Revenue Forecast and Analysis
6.2 Market Positioning of Key Players

7. United States Intravenous Immunoglobulin Market Analysis - by Type

7.1 Overview
7.2 United States Intravenous Immunoglobulin Market, by Type - Volume and Forecast to 2028 (Metric Tons)
7.3 United States Intravenous Immunoglobulin Market, by Type - Revenue and Forecast to 2028 (US$ Million)
7.4 IgG
- 7.4.1 Overview
- 7.4.2 IgG: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5 IgM
- 7.5.1 Overview
- 7.5.2 IgM: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6 IgA
- 7.6.1 Overview
- 7.6.2 IgA: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

8. United States Intravenous Immunoglobulin Market Analysis - by Application

8.1 Overview
8.2 United States Intravenous Immunoglobulin Market, by Application - Revenue and Forecast to 2028 (US$ Million)
8.3 Hypogammaglobulinemia
- 8.3.1 Overview
- 8.3.2 Hypogammaglobulinemia: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
8.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIPD)
- 8.4.1 Overview
- 8.4.2 CIPD: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
8.5 Immunodeficiency Diseases
- 8.5.1 Overview
- 8.5.2 Immunodeficiency Disease: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
8.6 Myasthenia Gravis
- 8.6.1 Overview
- 8.6.2 Myasthenia Gravis: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
8.7 Multifocal Motor Neuropathy
- 8.7.1 Overview
- 8.7.2 Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
8.8 Idiopathic Thrombocytopenic Purpura
- 8.8.1 Overview
- 8.8.2 Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market- Revenue and Forecast to 2028 (US$ Million)
8.9 Inflammatory Myopathies
- 8.9.1 Overview
- 8.9.2 Inflammatory Myopathies: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
8.10 Specific Antibody Deficiency
- 8.10.1 Overview
- 8.10.2 Specific Antibody Deficiency: United States Intravenous Immunoglobulin Market - Revenue and Forecast to 2028 (US$ Million)
8.11 Guillain-Barre Syndrome
- 8.11.1 Overview
- 8.11.2 Guillain-Barre Syndrome: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
8.12 Others
- 8.12.1 Overview
- 8.12.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

9. United States Intravenous Immunoglobulin Market Analysis - by Distribution Channel

9.1 Overview
9.2 United States Intravenous Immunoglobulin Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
9.3 Hospital Pharmacy
- 9.3.1 Overview
- 9.3.2 Hospital Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Retail Pharmacy
- 9.4.1 Overview
- 9.4.2 Retail Pharmacy: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
9.5 Others
- 9.5.1 Overview
- 9.5.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

10. United States Intravenous Immunoglobulin Market Analysis - by End User

10.1 Overview
10.2 United States Intravenous Immunoglobulin Market, by End User - Revenue and Forecast to 2028 (US$ Million)
10.3 Hospitals
- 10.3.1 Overview
- 10.3.2 Hospitals: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Specialty Clinics
- 10.4.1 Overview
- 10.4.2 Specialty Clinics: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)
10.5 Others
- 10.5.1 Overview
- 10.5.2 Others: United States Intravenous Immunoglobulins Market - Revenue and Forecast to 2028 (US$ Million)

11. United States Intravenous Immunoglobulin Market: Impact Assessment of COVID-19 Pandemic

11.1 US: Impact Assessment of COVID-19 Pandemic

12. US Intravenous Immunoglobulin Market - Industry Landscape

12.1 Overview
12.2 Growth Strategies in US Intravenous Immunoglobulin Market (%)
12.3 Organic Developments
- 12.3.1 Overview
12.4 Inorganic Developments
- 12.4.1 Overview

13. Company Profiles

13.1 Takeda Pharmaceutical Co Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Grifols SA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Pfizer Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd.
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Octapharma AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Kedrion SpA
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 CSL Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 LFB Group
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Prothya Biosolutions B.V.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms